valproic acid has been researched along with Cystic Fibrosis in 5 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 years old male with myoclonic epilepsy on Valproic acid (VPA) monotherapy, developed an acute pancreatitis." | 3.77 | VPA-induced recurrent pancreatitis in a cystic fibrosis carrier. ( Alexopoulou, E; Attilakos, A; Dinopoulos, A; Fretzayas, A; Karapanou, O; Tzetis, M, 2011) |
| "Valproic acid is a first-line anti-epileptic drug and a proven HDAC inhibitor." | 2.53 | Anti-fibrotic effects of valproic acid: role of HDAC inhibition and associated mechanisms. ( Ahirwar, K; Jena, G; Khan, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barone, S | 1 |
| Cassese, E | 1 |
| Alfano, AI | 1 |
| Brindisi, M | 1 |
| Summa, V | 1 |
| Nagai, Y | 1 |
| Limberis, MP | 1 |
| Zhang, H | 1 |
| Ramachandran, S | 1 |
| Osterhaus, SR | 1 |
| Karp, PH | 1 |
| Welsh, MJ | 1 |
| McCray, PB | 1 |
| Khan, S | 1 |
| Ahirwar, K | 1 |
| Jena, G | 1 |
| Dinopoulos, A | 1 |
| Karapanou, O | 1 |
| Alexopoulou, E | 1 |
| Tzetis, M | 1 |
| Attilakos, A | 1 |
| Fretzayas, A | 1 |
2 reviews available for valproic acid and Cystic Fibrosis
| Article | Year |
|---|---|
Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Histone Deacetylase 6 | 2022 |
Anti-fibrotic effects of valproic acid: role of HDAC inhibition and associated mechanisms.
Topics: Animals; Cystic Fibrosis; Epigenesis, Genetic; Fibrosis; Histone Deacetylase Inhibitors; Humans; Kid | 2016 |
3 other studies available for valproic acid and Cystic Fibrosis
| Article | Year |
|---|---|
Modulation of Treg function improves adenovirus vector-mediated gene expression in the airway.
Topics: Adaptive Immunity; Animals; Cystic Fibrosis; Dependovirus; Disease Models, Animal; Gene Transfer Tec | 2014 |
A genomic signature approach to rescue ΔF508-cystic fibrosis transmembrane conductance regulator biosynthesis and function.
Topics: Biperiden; Bronchi; Chlorides; Computational Biology; Cystic Fibrosis; Cystic Fibrosis Transmembrane | 2014 |
VPA-induced recurrent pancreatitis in a cystic fibrosis carrier.
Topics: Anticonvulsants; Child, Preschool; Cystic Fibrosis; Epilepsies, Myoclonic; Genetic Carrier Screening | 2011 |